Skip to main content

Biotechnology Value Fund L P's Form 4 filing

Repare Therapeutics Inc. (RPTX) · filed Nov 3, 2023

Accession no.
0000921895-23-002458
Filed
Nov 3, 2023, 5:37 PM ET
Trade date
Nov 2, 2023
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market purchases total $2.82M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Biotechnology Value Fund L PCIK 000091892310% Owner
BVF Partners L PCIK 000105594710% Owner
BVF IncCIK 000105680710% Owner
Biotechnology Value Fund II LPCIK 0001102444Other: See Explanation of Responses
Lampert Mark NCIK 000123384010% Owner
Biotechnology Value Trading Fund OS LPCIK 0001660683Other: See Explanation of Responses
BVF Partners OS Ltd.CIK 0001660684Other: See Explanation of Responses
BVF I GP LLCCIK 000180380510% Owner
BVF II GP LLCCIK 0001803806Other: See Explanation of Responses
BVF GP Holdings LLCCIK 000180380910% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 2, 2023Common Shares, no par valuePPurchaseAcquired+218,979$3.60+$788,324.44,662,402Direct
Nov 2, 2023Common Shares, no par valuePPurchaseAcquired+492,251$3.60+$1,772,103.63,792,157Direct
Nov 2, 2023Common Shares, no par valuePPurchaseAcquired+72,479$3.60+$260,924.4485,083Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)